GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Change In Inventory

BCRX (BioCryst Pharmaceuticals) Change In Inventory : $-1.1 Mil (TTM As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Change In Inventory?

BioCryst Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2024 was $-1.5 Mil. It means BioCryst Pharmaceuticals's inventory increased by $1.5 Mil from Jun. 2024 to Sep. 2024 .

BioCryst Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-1.5 Mil. It means BioCryst Pharmaceuticals's inventory increased by $1.5 Mil from Dec. 2022 to Dec. 2023 .

BioCryst Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2024 was $7.6 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BioCryst Pharmaceuticals's Days Inventory for the quarter that ended in Sep. 2024 was 169.78.

Inventory Turnover measures how fast the company turns over its inventory within a year. BioCryst Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.54.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioCryst Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.05.


BioCryst Pharmaceuticals Change In Inventory Historical Data

The historical data trend for BioCryst Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Change In Inventory Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.65 -7.04 -8.77 -12.42 -1.45

BioCryst Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.39 0.91 -1.22 0.74 -1.52

BioCryst Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals  (NAS:BCRX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioCryst Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=6.006/3.228*365 / 4
=169.78

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioCryst Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioCryst Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin director ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244